Bracco Diagnostics
RELATED CONTENT
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug Administration (FDA) approval for an extension to include magnetic resonance imaging (MRI) of the central nervous system (CNS) in pediatric patients younger than 2 years of age (including term neonates). The agent may now be used in this patient population to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine and associated tissues.
January 30, 2018 
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of ...
August 29, 2017 
Here are several updates in medical imaging contrast media agents. Two of the biggest news items were related to safety ...
July 28, 2017 
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to hospitals and radiology departments to control costs while meeting demand. In the CT suite, productivity and workflow can be impacted in several ways, but a new syringe-less, multi-dose multi-patient power injector is making waves at healthcare facilities with its efficiency-improving performance.
April 13, 2017 March 27, 2017 — Bracco Diagnostics Inc. announced the launch of its PROTOCO2L TOUCH Colon Insufflator. This device is ...
March 27, 2017 
With medical imaging use on the rise, contrast media use is expected to grow as well, according to a May 2016 report from market research firm GlobalData.
March 02, 2017 
At the 2016 Annual Meeting of the Radiological Society of North America (RSNA 2016), Bracco Diagnostics Inc. showcased a review of key milestones the company has achieved this year in diagnostic imaging and contrast media.
December 09, 2016 
Bracco Diagnostics Inc. announced that CT Exprès — the first and only multi-dose, multi-patient, syringe-less injector for computed tomography (CT) according to Bracco — is now available in the United States. The CT Exprès 3-D Contrast Media Delivery System is designed to streamline workflow and optimize patient care within the CT department.
December 05, 2016 The global market for contrast media is set to rise from just over $4.3 billion in 2015 to over $6 billion by 2022, according to research and consulting firm GlobalData. This represents a compound annual growth rate of 4.9 percent.
April 13, 2016 
Bracco Diagnostics Inc. announced that Lumason was approved by the Centers for Medicare and Medicaid Services (CMS) for pass-through status under the Hospital Outpatient Prospective Payment System (HOPPS). Lumason is an ultrasound contrast agent indicated for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
October 21, 2015